ResApp Health, now a subsidiary of Pfizer, Inc.

Digital healthcare for respiratory disease

ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease. We are creating easy to use, affordable, clinically-validated and regulatory-cleared diagnostic tools that only require a smartphone. Our solutions are designed to be easily integrated into existing telehealth solutions and we are also working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers.

About Respiratory Disease

A diagnosis of respiratory disease is one of the most common outcomes from visiting a doctor. Respiratory diseases can be caused by inflammation, bacterial infection or viral infection of the respiratory tract. Diseases caused by inflammation include chronic conditions such as asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD). Acute conditions, caused by either bacterial or viral infection, can affect either the upper or lower respiratory tract. Upper respiratory tract infections include common colds while lower respiratory tract infections include diseases such as pneumonia. Other infections include influenza, acute bronchitis and bronchiolitis.

Our Story

ResApp was founded in September 2014 to commercialise technology developed by Associate Professor Udantha Abeyratne that uses sound to diagnose respiratory disease. Associate Professor Abeyratne’s team has been engaged in the research and development of this technology since 2009 and has been funded by the Bill and Melinda Gates Foundation, The University of Queensland and UniQuest. ResApp listed on the Australian Stock Exchange in July 2015 and was named “Australian Emerging Company of the Year” at the Johnson & Johnson Innovation 2016 Industry Excellence Awards.

ResApp Logo White

ResApp Health Limited

ABN 51 094 468 318

138 Juliette Street

Greenslopes, QLD 4120, Australia

© 2023 ResApp Health Limited. All rights reserved.